Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Intellia Therapeutics, Inc. has 140.02M shares outstanding.

As of June 30, 2026, Intellia Therapeutics, Inc. maintains a current ratio of 6.65, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Intellia Therapeutics, Inc. posted a negative return on equity (ROE) of -55.44, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -45.55, reflecting losses generated across the asset base. The company generates approximately 135,816.43 in revenue per employee across its workforce of 383.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Intellia Therapeutics, Inc. generated 52.09M in revenue and converted that into -350.10M in net income, yielding earnings per share of -2.93. EBITDA reached -357.34M, while operating income came in at -370.67M.

As of June 30, 2026, Intellia Therapeutics, Inc. holds 383.17M in cash and equivalents against 64.26M in total debt, resulting in a net debt position of -92.89M. Total book value stands at 636.96M, with working capital of 392.52M providing operational flexibility.

Intellia Therapeutics, Inc. produced -303.42M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.79M in capital expenditures, free cash flow totaled -305.20M - equivalent to -2.55 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -711.66 and net profit margin of -672.16 provide insight into operational efficiency.